Granulomatose avec polyangéite : Questions médicales fréquentes
Nom anglais: Granulomatosis with Polyangiitis
Descriptor UI:D014890
Tree Number:C20.111.193.875
Termes MeSH sélectionnés :
Off-Label Use
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Granulomatose avec polyangéite : Questions médicales les plus fréquentes",
"headline": "Granulomatose avec polyangéite : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Granulomatose avec polyangéite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"url": "https://questionsmedicales.fr/mesh/D056648",
"about": {
"@type": "MedicalCondition",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"code": {
"@type": "MedicalCode",
"code": "D056648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.193"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite",
"alternateName": "Granulomatosis with Polyangiitis",
"code": {
"@type": "MedicalCode",
"code": "D014890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Benjamin Terrier",
"url": "https://questionsmedicales.fr/author/Benjamin%20Terrier",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr."
}
},
{
"@type": "Person",
"name": "Xavier Puéchal",
"url": "https://questionsmedicales.fr/author/Xavier%20Pu%C3%A9chal",
"affiliation": {
"@type": "Organization",
"name": "Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr."
}
},
{
"@type": "Person",
"name": "Christian Pagnoux",
"url": "https://questionsmedicales.fr/author/Christian%20Pagnoux",
"affiliation": {
"@type": "Organization",
"name": "Vasculitis Clinic, Division of Rheumatology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Roman Yatsyshyn",
"url": "https://questionsmedicales.fr/author/Roman%20Yatsyshyn",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine."
}
},
{
"@type": "Person",
"name": "Olena Zimba",
"url": "https://questionsmedicales.fr/author/Olena%20Zimba",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study.",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35695280",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09546634.2022.2089328"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-Inflammatory and Immunomodulatory Effect of High-Dose Immunoglobulins in Children: From Approved Indications to Off-Label Use.",
"datePublished": "2023-10-07",
"url": "https://questionsmedicales.fr/article/37830631",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells12192417"
}
},
{
"@type": "ScholarlyArticle",
"name": "Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.",
"datePublished": "2023-02-18",
"url": "https://questionsmedicales.fr/article/36804370",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijantimicag.2023.106763"
}
},
{
"@type": "ScholarlyArticle",
"name": "Off-label prescriptions in child and adolescent psychiatry. Why, when and how?",
"datePublished": "2022-12-30",
"url": "https://questionsmedicales.fr/article/36626604",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.53680/vertex.v33i158.320"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety Profile and Complication Rates in Emergency Off-label Use of Tirofiban in Interventional Neuroradiology : An Observational Dual Center Study.",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/36269346",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00062-022-01223-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"item": "https://questionsmedicales.fr/mesh/D056648"
},
{
"@type": "ListItem",
"position": 5,
"name": "Granulomatose avec polyangéite",
"item": "https://questionsmedicales.fr/mesh/D014890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Granulomatose avec polyangéite - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Granulomatose avec polyangéite",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Granulomatose avec polyangéite",
"description": "Comment diagnostiquer la granulomatose avec polyangéite ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nQuel rôle joue la biopsie dans le diagnostic ?\nQuels symptômes cliniques orientent vers cette maladie ?\nComment les examens d'imagerie aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Granulomatose avec polyangéite",
"description": "Quels sont les symptômes courants de cette maladie ?\nLa granulomatose affecte-t-elle les voies respiratoires ?\nQuels problèmes rénaux peuvent survenir ?\nY a-t-il des manifestations cutanées ?\nLes symptômes varient-ils d'un patient à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Granulomatose avec polyangéite",
"description": "Peut-on prévenir la granulomatose avec polyangéite ?\nComment éviter les complications ?\nLes vaccinations sont-elles recommandées ?\nY a-t-il des conseils de mode de vie à suivre ?\nLes patients doivent-ils éviter certains médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Granulomatose avec polyangéite",
"description": "Quels traitements sont utilisés pour cette maladie ?\nComment les corticostéroïdes aident-ils ?\nQuels sont les effets secondaires des traitements ?\nLa thérapie biologique est-elle une option ?\nQuelle est l'importance du suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Granulomatose avec polyangéite",
"description": "Quelles sont les complications possibles ?\nComment l'insuffisance rénale se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nQuels problèmes pulmonaires peuvent survenir ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Granulomatose avec polyangéite",
"description": "Quels sont les facteurs de risque connus ?\nLe tabagisme augmente-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nL'âge influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Off-Label+Use&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la granulomatose avec polyangéite ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps anti-PR3 et des marqueurs d'inflammation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'identifier les granulomes et l'inflammation des vaisseaux."
}
},
{
"@type": "Question",
"name": "Quels symptômes cliniques orientent vers cette maladie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, des éruptions cutanées et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Comment les examens d'imagerie aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les examens comme la radiographie ou l'IRM montrent des anomalies dans les poumons et les reins."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette maladie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, perte de poids, et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "La granulomatose affecte-t-elle les voies respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des sinusites, des saignements de nez et des toux persistantes."
}
},
{
"@type": "Question",
"name": "Quels problèmes rénaux peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des atteintes rénales peuvent entraîner une insuffisance rénale et des urines anormales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des manifestations cutanées ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées, des nodules et des ulcères peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la granulomatose avec polyangéite ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical peut aider."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et un suivi régulier permettent de réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent être recommandées pour prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils de mode de vie à suivre ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est conseillé."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains médicaments ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aggraver la maladie et doivent être évités."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour cette maladie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les corticostéroïdes aident-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils réduisent l'inflammation et soulagent les symptômes rapidement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux."
}
},
{
"@type": "Question",
"name": "La thérapie biologique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies biologiques ciblées peuvent être utilisées pour les cas réfractaires."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment l'insuffisance rénale se manifeste-t-elle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par une diminution de la production d'urine et un gonflement."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients sont plus susceptibles de développer des infections en raison du traitement."
}
},
{
"@type": "Question",
"name": "Quels problèmes pulmonaires peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications pulmonaires peuvent inclure des hémorragies et des nodules pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque significatif pour cette maladie."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher la maladie ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans."
}
}
]
}
]
}
Off-label uses of biologics in the treatment of psoriasis are usually implemented in limited-resource settings and studies regarding their response profiles are limited....
This was a retrospective study performed in moderate-to-severe plaque-type psoriasis patients who had been treated with either secukinumab, ixekizumab or brodalumab at a university hospital in Thailan...
A total of 142 patients were included in the data analysis consisting of three groups of 48 patients, 86 patients, and 8 patients treated by secukinumab, ixekizumab, and brodalumab, respectively. Pati...
Off-label, patient-oriented regimens could be a promising choice of IL-17 inhibitors for administration in special settings. Off-label regimens are not inferior in terms of skin clearance to an on-lab...
The large-scale utilization of immunoglobulins in patients with inborn errors of immunity (IEIs) since 1952 prompted the discovery of their key role at high doses as immunomodulatory and anti-inflamma...
To provide pragmatic indications for a need-based application of high-dose immunoglobulins in the pediatric context....
A literature search was performed using PubMed, from inception until 1st August 2023, including the following keywords: anti-inflammatory; children; high dose gammaglobulin; high dose immunoglobulin; ...
In the light of the current imbalance between gammaglobulins' demand and availability, this review advocates the urgency of a more conscious utilization of this medical product, giving indications abo...
The infections caused by multidrug- and extensively drug-resistant (MDR, XDR) bacteria, including Gram-positive cocci (GPC, including methicillin-resistant Staphylococcus aureus, MDR-Streptococcus pne...
In the paediatric population, paticulary in the field of child and adolescent psychiatry, off-label indications are the rule rather than the exception. This may occur when a drug is indicated for a pa...
Tirofiban has been approved for the treatment of acute coronary syndrome. Meanwhile, tirofiban is frequently applied in emergency situations in interventional neuroradiology (INR). The objective of th...
Data of 86 patients, who underwent neurointerventional therapy and were treated with tirofiban at 2 neuroendovascular centers between January 2016 and July 2017 were retrospectively analyzed. Despite ...
Median patient age was 62 years (range 26-88 years). Patients received tirofiban for extracranial (n = 35) or intracranial stenting (n = 35), coiling of ruptured cerebral aneurysms (n = 6), continuous...
Whereas the safety profile of tirofiban when applied off-label in INR is acceptable, the highest risk for relevant tirofiban-associated complications is observed in older patients treated by emergency...
Introduction. In pediatric intensive care units, a large number of drugs are used, many of which are prescribed for condition beyond those established in their summary of product characteristics (off-...
Type 2 immune response refers to a complicated series of immune responses characterized by Th2 polarization and Th2 cytokines secretion. The IgE secretion, airway hypersensitivity, and effector cell r...
Off-label medicines use is a common and sometimes necessary practice in many populations, with important clinical, ethical and financial consequences, including potential unintended harm or lack of ef...
We conducted a scoping review to summarize the literature on available off-label use guidance, including types, extent and scientific rigor of evidence incorporated. Findings informed the development ...
We found 31 published guidance documents on therapeutic decision-making for off-label use. Of 20 guidances with general recommendations, only 35% detailed the types and quality of evidence needed and ...
We provide comprehensive consensus recommendations to optimize therapeutic decision-making for off-label medicines use and concurrently drive clinically relevant research. Successful implementation re...
This paper investigates the effect of scientific information from randomized controlled clinical trials (RCTs) on the demand for off-label uses of cancer drugs. This is a unique setting where demand f...
Methotrexate (MTX) is characterized as first-line therapy although its indication of ectopic pregnancy is off-label use. We aimed to conduct a retrospective cohort study to investigate the incidence, ...
Basing on China Hospital Pharmacovigilance System (CHPS), a retrospective analysis was performed to evaluate the safety of MTX (...
The total incidence of ADRs was 54.0%. Anaemia (37.6%) was the most frequent ADR, followed by hepatic function abnormal (11.3%), hyperuricemia (6.1%), neutropenia (4.6%), leukopenia (4.0%), and dyslip...
MTX is quite safe in ectopic pregnancy, despite its mild to moderate hematotoxicity, hepatotoxicity and nephrotoxicity. Taking CHPS can present the accurate denominator of the incidence of adverse dru...